Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Chief Financial Officer | August 19, 2024 | August 20, 2024 |
| EQRx, Inc.EQRX · Entity 108311 | Chief Financial Officer | January 01, 2023 | January 04, 2023 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 06, 2025 | June 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date August 19, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2033-07-25 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-19 · Disposition to issuer · Disposed 196,666 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F1: The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.19 · Expires 2034-02-14 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-19 · Disposition to issuer · Disposed 51,420 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F3: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2034-03-26 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-19 · Disposition to issuer · Disposed 32,468 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F4: The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2033-07-25 | Direct | 196,666 |
Reported balance
After 2024-08-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-19 · Grant · Acquired 196,666 · Balance 196,666 F5: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F1: The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2034-02-14 | Direct | 51,420 |
Reported balance
After 2024-08-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-19 · Grant · Acquired 51,420 · Balance 51,420 F5: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F3: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2034-03-26 | Direct | 32,468 |
Reported balance
After 2024-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-19 · Grant · Acquired 32,468 · Balance 32,468 F5: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F4: The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024.
F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged.
F3: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
F4: The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024.
F5: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.
EQRx, Inc.
Report date January 01, 2023 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17 | Direct | 302,203 |
Reported balance
After 2023-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-01 · Grant · Acquired 1,585 · Balance 302,203 F1: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). |
Filing footnotes · ownership attribution and instrument terms
F1: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).
Relay Therapeutics, Inc.
Report date June 06, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.36 · Expires 2035-06-05 | Direct | 136,681 |
Reported balance
After 2025-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-06 · Grant · Acquired 136,681 · Balance 136,681 F1: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2025 Filed Jun 6, 2025 17:50 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 136,681 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000950170-25-083305 · ownership.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,681 Underlying: Common Stock · 136,681 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:03 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 32,468 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099296 · ownership.xml · derivative · entry 6 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,468 Underlying: Common Stock · 32,468 shares Expires 2034-03-26 F5 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:03 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 51,420 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099296 · ownership.xml · derivative · entry 5 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,420 Underlying: Common Stock · 51,420 shares Expires 2034-02-14 F5 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:03 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 196,666 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099296 · ownership.xml · derivative · entry 4 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,666 Underlying: Common Stock · 196,666 shares Expires 2033-07-25 F5 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:03 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 32,468 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-099296 · ownership.xml · derivative · entry 3 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,468 shares Expires 2034-03-26 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:03 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 51,420 | Not disclosed Strike: $8.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-099296 · ownership.xml · derivative · entry 2 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,420 shares Expires 2034-02-14 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:03 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 196,666 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099296 · ownership.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,666 shares Expires 2033-07-25 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 16:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,242 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000950170-24-072426 · ownership.xml · derivative · entry 2 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,242 shares Expires 2029-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. F2 · derivative.exercise_date: This stock option vested in sixteen (16) equal quarterly installments following the vesting commencement date of October 10, 2019, subject to the reporting person's continued service relationship through each vesting date. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 16:06 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 42,242 | $5.04 | $212,899.68 |
DisclosureSEC source: 0000950170-24-072426 · ownership.xml · nonDerivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:04 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 102,225 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000950170-24-069558 · ownership.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,225 Underlying: Common Stock · 102,225 shares Expires 2034-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 16:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 32,468 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038702 · ownership.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,468 Underlying: Common Stock · 32,468 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 18:36 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 66,055 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001209191-23-033434 · doc4.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,055 Underlying: Common Stock · 66,055 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:56 UTC | EQRx, Inc. EQRX · Entity 108311 | GrantEarn-out Shares · Derivative | 1,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-001118 · tm231679-9_4seq1.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,203 Underlying: Common Stock · 1,585 shares Expires 2024-12-17 F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.). Read SEC document |
| May 27, 2022 Filed May 27, 2022 17:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 41,597 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001209191-22-032671 · doc4.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Common Stock · 41,597 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 17:36 UTC | EQRx, Inc. EQRX · Entity 108311 | GrantStock Option (Right to Buy) · Derivative | 515,601 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001213900-22-010138 · ownership.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,601 Underlying: Common Stock · 515,601 shares Expires 2032-02-25 F1 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing February 1, 2022, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:58 UTC | EQRx, Inc. EQRX · Entity 108311 | GrantEarn-out Shares · Derivative | 300,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049100 · doc4.xml · derivative · entry 2 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,618 Underlying: Common Stock · 300,618 shares Expires 2024-12-17 F2 · derivative.exercise_price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 210,433 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F2 · kind: Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 210,433 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F2 · price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 210,433 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F2 · derivative.exercise_date: Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 210,433 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:58 UTC | EQRx, Inc. EQRX · Entity 108311 | GrantCommon Stock | 2,194,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049100 · doc4.xml · nonDerivative · entry 1 Rubin Jami · CIK 0001816484 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,194,500 F1 · kind: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. F1 · price: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. Read SEC document |
| May 19, 2021 Filed May 21, 2021 19:45 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001209191-21-035115 · doc4.xml · derivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 19:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0000899243-20-019842 · doc4.xml · nonDerivative · entry 1 Rubin Jami · CIK 0001816484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: On July 20, 2020, the Reporting Person purchased 25,000 shares of common stock, par value $0.001 per share, of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.